Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paraldehyde is a small molecule central nervous system depressant and anticonvulsant that has historically been used to treat certain convulsive disorders such as status epilepticus and tetanus. It has also been used as a sedative, hypnotic, and in the management of alcoholism and agitation in psychiatric conditions. Paraldehyde acts by depressing neuronal activity in the brain; its mechanism is believed to involve enhancement of GABAergic activity (increasing inhibitory effects on neuronal excitability) and reduction of acetylcholine release during neuronal depolarization, though the precise mechanism remains unclear. Its use has largely been replaced by safer alternatives but it may still be employed for refractory seizures when other treatments fail[1][2][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paraldehyde.